Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Joint Venture, Subsidiary
- Established
- 1997-04-16
- Employees
- -
- Market Cap
- -
- Website
- http://www.cttq.com
A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer
- First Posted Date
- 2020-05-22
- Last Posted Date
- 2020-09-11
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 71
- Registration Number
- NCT04398940
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳Sir Run Shaw Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Hangzhou, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, Hangzhou, China
A Study of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL)
- First Posted Date
- 2020-05-22
- Last Posted Date
- 2020-09-11
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 102
- Registration Number
- NCT04398953
- Locations
- 🇨🇳
Anhui Cancer Hospital, Hefei, Anhui, China
🇨🇳The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Beijing Boren Hospital, Beijing, Beijing, China
A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.
- Conditions
- Interventions
- First Posted Date
- 2020-05-13
- Last Posted Date
- 2020-05-13
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 338
- Registration Number
- NCT04385563
- Locations
- 🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma
- First Posted Date
- 2020-05-13
- Last Posted Date
- 2020-05-13
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 528
- Registration Number
- NCT04385550
- Locations
- 🇨🇳
Xinxiang Central Hospital, Xinxiang, Henan, China
🇨🇳The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳The Sixth Medical Center of PLA General Hospital, Beijing, Beijing, China
Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2020-05-05
- Last Posted Date
- 2020-07-08
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 424
- Registration Number
- NCT04373967
- Locations
- 🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳The Second People's Hospital of Heifei, Hefei, Anhui, China
🇨🇳Yijishan Hospital of Wannan Medical College, Wuhu, Anhui, China
A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2020-04-21
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT04355520
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳The First Hospital of Jilin university, Changchun, Jilin, China
A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
- Conditions
- Interventions
- First Posted Date
- 2020-04-14
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 648
- Registration Number
- NCT04344158
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳Anhui Provincial Cancer Hospital, Hefei, Anhui, China
A Study of TQB3455 Tablets in Subjects With Advanced Malignancies
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2020-07-01
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT04340427
- Locations
- 🇨🇳
Chongqing University Cancer Hospital, Chongqing, Chongqing, China
A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2020-04-09
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT04339400
- Locations
- 🇨🇳
Hematology Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
🇨🇳West China Hospital ,Sichuan University, Chendu, Sichuan, China
A Study of AL2846 Capsule Combined With Standard Chemotherapy Regimen in Subjects With Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2020-07-21
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT04337879
- Locations
- 🇨🇳
The First Hospital of China Medical University, Shengyang, Liaoning, China